

Finbar Jk O'callaghan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5984195/publications.pdf>

Version: 2024-02-01

102
papers

9,467
citations

66234

42
h-index

38300

95
g-index

102
all docs

102
docs citations

102
times ranked

9217
citing authors

#	ARTICLE	IF	CITATIONS
1	Epilepsy and cannabis: so near, yet so far. <i>Developmental Medicine and Child Neurology</i> , 2022, 64, 162-167.	1.1	3
2	The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial. <i>EClinicalMedicine</i> , 2021, 32, 100715.	3.2	13
3	TuberOus SCLerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex. <i>Frontiers in Neurology</i> , 2021, 12, 630378.	1.1	10
4	Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. <i>JAMA Neurology</i> , 2021, 78, 285.	4.5	139
5	Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SCLerosis registry to increAse disease awareness (TOSCA). <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 301.	1.2	15
6	Historical Patterns of Diagnosis, Treatments, and Outcome of Epilepsy Associated With Tuberous Sclerosis Complex: Results From TOSCA Registry. <i>Frontiers in Neurology</i> , 2021, 12, 697467.	1.1	13
7	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. <i>Pediatric Neurology</i> , 2021, 123, 50-66.	1.0	230
8	Foreword. <i>Developmental Medicine and Child Neurology</i> , 2021, 63, 3-3.	1.1	0
9	Long-term cognitive outcomes in tuberous sclerosis complex. <i>Developmental Medicine and Child Neurology</i> , 2020, 62, 322-329.	1.1	35
10	Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas. <i>Frontiers in Neurology</i> , 2020, 11, 972.	1.1	27
11	Diagnostic algorithm for children presenting with epilepsy partialis continua. <i>Epilepsia</i> , 2020, 61, 2224-2233.	2.6	5
12	Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project. <i>Journal of Neurodevelopmental Disorders</i> , 2020, 12, 24.	1.5	16
13	Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings From the TOSCA Study. <i>Frontiers in Neurology</i> , 2020, 11, 904.	1.1	20
14	Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. <i>BMJ, The</i> , 2020, 368, m331.	3.0	53
15	Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND): New Findings on Age, Sex, and Genotype in Relation to Intellectual Phenotype. <i>Frontiers in Neurology</i> , 2020, 11, 603.	1.1	7
16	Prophylactic Antiepileptic Treatment in Tuberous Sclerosis. <i>Pediatric Neurology</i> , 2020, 110, 100-101.	1.0	1
17	The underlying etiology of infantile spasms (West syndrome): Information from the International Collaborative Infantile Spasms Study (<scpi>ICISS</scpi>). <i>Epilepsia</i> , 2019, 60, 1861-1869.	2.6	48
18	Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study. <i>Frontiers in Neurology</i> , 2019, 10, 821.	1.1	18

#	ARTICLE	IF	CITATIONS
19	Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. <i>Frontiers in Neurology</i> , 2019, 10, 705.	1.1	22
20	Quality of life in patients with Tuberous Sclerosis Complex (TSC). <i>European Journal of Paediatric Neurology</i> , 2019, 23, 801-807.	0.7	20
21	Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry. <i>Frontiers in Neurology</i> , 2019, 10, 1144.	1.1	11
22	The TOSCA Registry for Tuberous Sclerosisâ€™ Lessons Learnt for Future Registry Development in Rare and Complex Diseases. <i>Frontiers in Neurology</i> , 2019, 10, 1182.	1.1	3
23	Childhood haemorrhagic stroke: a 7-year single-centre experience. <i>Archives of Disease in Childhood</i> , 2019, 104, 1198-1202.	1.0	6
24	Cannabis derived medicinal products in child neurology. <i>Developmental Medicine and Child Neurology</i> , 2019, 61, 622-622.	1.1	0
25	Tuberous Sclerosis Complex (TSC): Expert Recommendations for Provision of Coordinated Care. <i>Frontiers in Neurology</i> , 2019, 10, 1116.	1.1	11
26	Epilepsy in tuberous sclerosis complex: Findings from the <sc>TOSCA</sc> Study. <i>Epilepsia Open</i> , 2019, 4, 73-84.	1.3	125
27	The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 37-46.	1.1	70
28	The UK guidelines for management and surveillance of Tuberous Sclerosis Complex. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2019, 112, 171-182.	0.2	26
29	Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the Tuberous Sclerosis registry to increase disease Awareness. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 502-508.	0.4	55
30	The essential symbiosis of academic and clinical neurology. <i>Developmental Medicine and Child Neurology</i> , 2018, 60, 5-5.	1.1	0
31	Secular changes in severity of intellectual disability in tuberous sclerosis complex: A reflection of improved identification and treatment of epileptic spasms?. <i>Epilepsia Open</i> , 2018, 3, 276-280.	1.3	10
32	Prospective studies of the incidence of pediatric arterial ischaemic stroke. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 69, 101.	0.6	3
33	A machine learning approach to identify cases of cerebral palsy using the UK primary care database. <i>Lancet, The</i> , 2018, 392, S33.	6.3	6
34	Diagnosis of tuberous sclerosis complex in the fetus. <i>European Journal of Paediatric Neurology</i> , 2018, 22, 1027-1034.	0.7	46
35	Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 715-725.	2.7	114
36	TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 157.	1.2	106

#	ARTICLE	IF	CITATIONS
37	Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations. <i>European Journal of Paediatric Neurology</i> , 2018, 22, 738-748.	0.7	151
38	Tuberous Sclerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patients. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 2.	1.2	166
39	Planning interventional trials in childhood arterial ischaemic stroke using a Delphi consensus process. <i>Developmental Medicine and Child Neurology</i> , 2017, 59, 713-718.	1.1	21
40	Immunotherapy for arterial ischaemic stroke in childhood: a systematic review. <i>Archives of Disease in Childhood</i> , 2017, 102, 410-415.	1.0	11
41	Causes of mortality in individuals with tuberous sclerosis complex. <i>Developmental Medicine and Child Neurology</i> , 2017, 59, 612-617.	1.1	87
42	Epileptic spasms – 175 years on: Trying to teach an old dog new tricks. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2017, 44, 81-86.	0.9	38
43	Musculoskeletal involvement in tuberous sclerosis. <i>Archives of Disease in Childhood</i> , 2017, 102, 178-178.	1.0	0
44	Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. <i>Lancet Neurology</i> , The, 2017, 16, 33-42.	4.9	199
45	CAUSES OF MORTALITY IN INDIVIDUALS WITH TUBEROUS SCLEROSIS COMPLEX (TSC). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, e1.207-e1.	0.9	0
46	Outcome and recurrence 1 year after pediatric arterial ischemic stroke in a population-based cohort. <i>Annals of Neurology</i> , 2016, 79, 784-793.	2.8	51
47	Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. <i>Neuroepidemiology</i> , 2015, 45, 161-176.	1.1	1,002
48	Outcomes following childhood arterial ischaemic stroke: A Delphi Consensus on what parents want from future research. <i>European Journal of Paediatric Neurology</i> , 2015, 19, 181-187.	0.7	11
49	Epilepsy in childhood and quality of life. <i>European Journal of Paediatric Neurology</i> , 2015, 19, 276-277.	0.7	0
50	Diagnostic delays in paediatric stroke. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 917-921.	0.9	92
51	TOSCA – first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 182.	1.2	62
52	Childhood arterial ischaemic stroke incidence, presenting features, and risk factors: a prospective population-based study. <i>Lancet Neurology</i> , The, 2014, 13, 35-43.	4.9	291
53	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 243-254.	1.0	1,185
54	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 255-265.	1.0	693

#	ARTICLE	IF	CITATIONS
55	The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. <i>European Journal of Paediatric Neurology</i> , 2013, 17, 36-44.	0.7	33
56	Glossal hamartoma in tuberous sclerosis. <i>Archives of Disease in Childhood</i> , 2013, 98, 161-161.	1.0	3
57	An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms. <i>Developmental Medicine and Child Neurology</i> , 2013, 55, 862-867.	1.1	36
58	External hydrocephalus and subdural bleeding in infancy associated with transplacental anti-Ro antibodies. <i>Archives of Disease in Childhood</i> , 2012, 97, 316-319.	1.0	5
59	The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: Evidence from the United Kingdom Infantile Spasms Study. <i>Epilepsia</i> , 2011, 52, 1359-1364.	2.6	215
60	Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. <i>Lancet Neurology</i> , The, 2011, 10, 54-62.	4.9	179
61	Juvenile parkinsonism associated with heterozygous frameshift ATP13A2 gene mutation. <i>European Journal of Paediatric Neurology</i> , 2011, 15, 271-275.	0.7	18
62	The epidemiology of childhood stroke. <i>European Journal of Paediatric Neurology</i> , 2010, 14, 197-205.	0.7	75
63	The underlying etiology of infantile spasms (West syndrome): Information from the United Kingdom Infantile Spasms Study (UKISS) on contemporary causes and their classification. <i>Epilepsia</i> , 2010, 51, 2168-2174.	2.6	194
64	Mortality from childhood stroke in England and Wales, 1921-2000. <i>Archives of Disease in Childhood</i> , 2010, 95, 12-19.	1.0	32
65	Treatment of primary angiitis of the central nervous system in childhood with mycophenolate mofetil. <i>Rheumatology</i> , 2010, 49, 806-811.	0.9	54
66	Phospholipase C beta 1 deficiency is associated with early-onset epileptic encephalopathy. <i>Brain</i> , 2010, 133, 2964-2970.	3.7	95
67	Risk factors and treatment outcomes of childhood stroke. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1331-1346.	1.4	19
68	Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. <i>Archives of Disease in Childhood</i> , 2010, 95, 382-386.	1.0	138
69	Cerebral venous sinus thrombosis: a case series including thrombolysis. <i>Archives of Disease in Childhood</i> , 2009, 94, 790-794.	1.0	38
70	Running an international paediatric non-commercial clinical trial. <i>Archives of Disease in Childhood</i> , 2009, 94, 729-733.	1.0	3
71	Research governance delays for a multicentre non-interventional study. <i>Journal of the Royal Society of Medicine</i> , 2009, 102, 195-198.	1.1	21
72	Oily fish intake during pregnancy – association with lower hyperactivity but not with higher full-scale IQ in offspring. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2008, 49, 1061-1068.	3.1	96

#	ARTICLE	IF	CITATIONS
73	Tuberous sclerosis--what's new?. Archives of Disease in Childhood, 2008, 93, 728-731.	1.0	19
74	Subependymal nodules, giant cell astrocytomas and the tuberous sclerosis complex: a population-based study. Archives of Disease in Childhood, 2008, 93, 751-754.	1.0	48
75	The Relative Effect of Size at Birth, Postnatal Growth and Social Factors on Cognitive Function in Late Childhood. Annals of Epidemiology, 2006, 16, 469-476.	0.9	48
76	Duration of Breast Feeding and Cognitive Function: Population Based Cohort Study. European Journal of Epidemiology, 2006, 21, 435-441.	2.5	18
77	Psychopathology in tuberous sclerosis: an overview and findings in a population-based sample of adults with tuberous sclerosis. Journal of Intellectual Disability Research, 2006, 50, 561-569.	1.2	39
78	The Influence of Head Growth in Fetal Life, Infancy, and Childhood on Intelligence at the Ages of 4 and 8 Years. Pediatrics, 2006, 118, 1486-1492.	1.0	252
79	CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients. Journal of Medical Genetics, 2006, 43, 729-734.	1.5	167
80	The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurology, The, 2005, 4, 712-717.	4.9	354
81	Melatonin Excretion in Normal Children and in Tuberous Sclerosis Complex With Sleep Disorder Responsive to Melatonin. Journal of Child Neurology, 2005, 20, 21-25.	0.7	17
82	Effect of Melatonin Dosage on Sleep Disorder in Tuberous Sclerosis Complex. Journal of Child Neurology, 2005, 20, 78-80.	0.7	40
83	Status epilepticus: Beyond guidelines. Current Paediatrics, 2005, 15, 324-332.	0.2	1
84	Epilepsy related mortality. Archives of Disease in Childhood, 2004, 89, 705-707.	1.0	6
85	The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Archives of Disease in Childhood, 2004, 89, 530-533.	1.0	189
86	An epidemiological study of renal pathology in tuberous sclerosis complex. BJU International, 2004, 94, 853-857.	1.3	168
87	Critical periods of brain growth and cognitive function in children. Brain, 2004, 127, 321-329.	3.7	247
88	The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet, The, 2004, 364, 1773-1778.	6.3	320
89	The management of tuberous sclerosis. Current Paediatrics, 2003, 13, 365-370.	0.2	0
90	Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychological Medicine, 2003, 33, 335-344.	2.7	261

#	ARTICLE	IF	CITATIONS
91	Autism—what is it and where does it come from?. QJM - Monthly Journal of the Association of Physicians, 2002, 95, 263-265.	0.2	2
92	Shaken impact syndrome. Lancet, The, 2001, 357, 1207.	6.3	1
93	Ophthalmic manifestations of tuberous sclerosis: a population based study. British Journal of Ophthalmology, 2001, 85, 420-423.	2.1	203
94	Trends in Epilepsy Mortality in England and Wales and the United States, 1950-1994. American Journal of Epidemiology, 2000, 151, 182-189.	1.6	20
95	Recent advances: Advances in the understanding of tuberous sclerosis. Archives of Disease in Childhood, 2000, 83, 140-142.	1.0	35
96	Renal angiomyolipomata and learning difficulty in tuberous sclerosis complex. Journal of Medical Genetics, 2000, 37, 156-157.	1.5	16
97	Non-penetrance in tuberous sclerosis. Lancet, The, 2000, 355, 1698.	6.3	36
98	Use of melatonin to treat sleep disorders in tuberous sclerosis. Developmental Medicine and Child Neurology, 1999, 41, 123-126.	1.1	77
99	Infantile spasms and vigabatrin. BMJ: British Medical Journal, 1999, 318, 56-56.	2.4	6
100	Prevalence of tuberous sclerosis in UK. Lancet, The, 1998, 352, 319.	6.3	3
101	Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet, The, 1998, 351, 1490.	6.3	210
102	Tuberous sclerosis complex and Wolff-Parkinson-White syndrome. Archives of Disease in Childhood, 1998, 78, 159-162.	1.0	63